Double-Pronged attack: new CAR T-Cell therapy targets Hard-to-Treat myeloma

NCT ID NCT06235229

Recruiting now Disease control Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called GC012F for people with multiple myeloma that has come back or not responded to at least three prior treatments. GC012F is a type of immunotherapy that uses a patient's own immune cells, modified to recognize and attack myeloma cells using two targets (CD19 and BCMA). The trial will enroll 110 participants to evaluate safety and how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GC012F (a dual-target CAR T-cell therapy that attacks cancer cells using two markers, CD19 and BCMA)
What this could lead to: If successful, this could offer a new treatment option for patients with multiple myeloma that has not responded to other therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of participants, so results may not apply broadly. CAR T-cell therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Research Site
ACTIVE_NOT_RECRUITING

Beijing, 100024, China
Research Site
RECRUITING

Beijing, 102200, China
Research Site
RECRUITING

Hangzhou, 310003, China
Research Site
RECRUITING

Jinan, 250117, China
Research Site
RECRUITING

Shanghai, 200003, China
Research Site
RECRUITING

Shanghai, 201210, China
Research Site
RECRUITING

Shenyang, 110134, China
Research Site
RECRUITING

Wenzhou, 325000, China
Research Site
RECRUITING

Wuhan, 430030, China
Research Site
ACTIVE_NOT_RECRUITING

Xi'an, 710004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.